Drugs decreasing plaque volume: high-intensity statins, PCSK9 inhibitors, ezetimibe (+statin), icosapent ethyl.
These also reduce cardiac events (MACE).
Numerically lower CV deaths: statins, icosapent ethyl, some PCSK9i data, colchicine, bempedoic (primary prev).
Statistically lower events: all listed lipid drugs + colchicine (MACE trials).
All-cause mortality: robust for statins; mixed/numerical for others (IPE, alirocumab); not for ezetimibe, bempedoic overall, colchicine.
Unclear event/mortality but used by metabolic docs: nattokinase, K2/MK7.